Yervoy Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Combo Ipilimumab + Nivolumab in Histologies of Bladder Cancer
Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber Cancer Institute offers his insight on the... Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

Nivolumab + Ipilimumab Combo Therapy In Patients with aHCC Results From CheckMate 040: ORR of 14 & mOS of 16 Months, First Report of Efficacy & Safety of The NIVO + IPI combo in SOR-Treated patients With aHCC
Thomas Yau MD, MBBS Of University of Hong Kong Discusses Nivolumab + Ipilimumab Combo Therapy In Patients with aHCC Results From CheckMate 040: ORR of 14& mOS of 16 Months, First Report of Efficacy & ... Author: Annual-Meeting Added: 06/13/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 14, 2019 Category: Cancer & Oncology Source Type: podcasts

Toxicity Of Nivolumab & Ipilimumab: Were Still Learning How To Leverage These Treatments In The Pre-Operative Setting
Tina Cascone MD Of The University of Texas MD Anderson Cancer Center Discusses Toxicity Of Nivolumab & Ipilimumab: Were Still Learning How To Leverage These Treatments In The Pre-Operative Setting. ... Author: Annual-Meeting Added: 06/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2019 Category: Cancer & Oncology Source Type: podcasts

Results Of NEOSTAR Study: Study Looked At Neoadjuvant Nivolumab Or Nivolumab Plus Ipilimumab For Resectable NSCLC
Tina Cascone MD Of The University of Texas MD Anderson Cancer Center Discusses Results Of NEOSTAR Study: Study Looked At Neoadjuvant Nivolumab Or Nivolumab Plus Ipilimumab For Resectable NSCLC. ... Author: Annual-Meeting Added: 06/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2019 Category: Cancer & Oncology Source Type: podcasts

United States Intergroup E1609 A phase III randomized study of adjuvant ipilimumab 3 or 10 mg kg versus high-dose interferon-2b for resected high-risk melanoma
Ahmad Tarhini Md, PhD of the Winship Cancer Center discusses the United States Intergroup E1609 A phase III randomized study of adjuvant ipilimumab 3 or 10 mg kg versus high-dose interferon-2b for re... Author: Annual-Meeting Added: 06/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 1, 2019 Category: Cancer & Oncology Source Type: podcasts

ILLUMINATE 301 A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Marcus Butler, MD of Princess Margaret Cancer Centre discusses the ILLUMINATE 301 A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients w... Author: Annual-Meeting Added: 05/31/2019 (Source: Oncology Tube)
Source: Oncology Tube - May 31, 2019 Category: Cancer & Oncology Source Type: podcasts

JAMA Dermatology : Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab vs Ipilimumab Alone for Unresectable Melanoma
Interview with Ivo Abraham, PhD, author of Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - November 21, 2018 Category: General Medicine Source Type: podcasts

Ipilimumab plus Nivolumab as Salvage Therapy in Patients with Checkpoint Inhibitor-Refractory Metastatic Renal Cell Carcinoma
Kimberly Allman, MSN, CNP Cleveland Clinic Taussig Cancer Institute discusses Ipilimumab plus Nivolumab as Salvage Therapy in Patients with Checkpoint Inhibitor-Refractory Metastatic... Author: kidneycancer Added: 11/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - November 6, 2018 Category: Cancer & Oncology Source Type: podcasts

Treatment-Free Survival Following Discontinuation of First-Line Nivolumab Plus Ipilimumab or Sunitinib
Thomas Powles Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, UK discusses Treatment-Free Survival Following Discontinuation... Author: kidneycancer Added: 11/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - November 5, 2018 Category: Cancer & Oncology Source Type: podcasts

Ipilimumab & Nivolumab Combo
Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses Ipilimumab & Nivolumab Combo. At Kidney Cancer Association National Patient and C... Author: kidneycancer Added: 10/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 5, 2018 Category: Cancer & Oncology Source Type: podcasts

Thoughts on Keynote 427 - Single Agent Pembrolizumab
David I. Quinn, MD, explains discusses Keynote 427 for Pembrolizumab, PD-1 Inhibitor and CTLA4 with Nivolumab & Ipilimumab presented at the 2018 ASCO Annual Meeting. Author: obr Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts

The outcomes of the Checkmate 142 study in mCRC
Atrayee Basu Mallick, MD, shares her thoughts on the outcomes of the Checkmate 142 study looking ipilimumab and nivolumab in metastatic colorectal cancer (mCRC) patients at ASCO 2018. Author: obr Added: 07/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 20, 2018 Category: Cancer & Oncology Source Type: podcasts

The outcomes of Checkmate 142 in mCRC
John Leighton, MD, shares the outcomes of the Checkmate 142 study examining ipilimumab and nivolumab in metastatic colorectal cancer (mCRC) patients at ASCO 2018. Author: obr Added: 07/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 20, 2018 Category: Cancer & Oncology Source Type: podcasts

Perspective on I-O failures
Robert A. Figlin, MD, talks about the best actions to take if newly diagnosed advanced renal cell carcinoma (RCC) patients receive nivolumab & ipilimumab but continues to progress at ASCO 2018. Author: obr Added: 07/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Is Nivo/Ipi the Treatment of Choice for Patients with Advanced NSCLC, Tumor PD-L1 & lt;1%, & amp; High TMB? New Data from CheckMate 227 (BMIC-040)
Dr. Jack West reviews data from the CheckMate 227 trial in patients with advanced NSCLC & tumor PD-L1 <1% that suggests potential utility of the nivolumab/ipilimumab (nivo/ipi) combination in p... Author: BeaconMedIC Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2018 Category: Cancer & Oncology Source Type: podcasts